0 10 Inhibition Inhibition NNP 11 13 of of IN 14 21 nuclear nuclear JJ 22 28 factor factor NN 29 35 kappaB kappab NN 36 46 activation activation NN 47 57 attenuates attenuate VBZ 58 67 apoptosis apoptosis NN 68 78 resistance resistance NN 79 81 in in IN 82 90 lymphoid lymphoid JJ 91 96 cells cell NNS 96 97 . . . 99 113 Death-inducing death-inducing JJ 114 121 ligands ligand NNS 122 123 ( ( ( 123 127 DILs DIL NNP 127 128 ) ) ) 129 133 such such JJ 134 136 as as IN 137 142 tumor tumor NN 143 151 necrosis necrosis NN 152 158 factor factor NN 159 164 alpha alpha NN 165 166 ( ( ( 166 174 TNFalpha TNFalpha NNP 174 175 ) ) ) 176 178 or or CC 179 182 the the DT 183 192 cytotoxic cytotoxic JJ 193 197 drug drug NN 198 209 doxorubicin doxorubicin NN 210 214 have have VBP 215 219 been be VBN 220 225 shown show VBN 226 228 to to TO 229 237 activate activate VB 238 239 a a DT 240 247 nuclear nuclear JJ 248 254 factor factor NN 255 261 kappaB kappaB NNP 262 263 ( ( ( 263 282 NFkappaB)-dependent nfkappab)-dependent JJ 283 290 program program NN 291 295 that that WDT 296 299 may may MD 300 306 rescue rescue VB 307 312 cells cell NNS 313 317 from from IN 318 327 apoptosis apoptosis NN 328 337 induction induction NN 337 338 . . . 339 341 We we PRP 342 353 demonstrate demonstrate VBP 354 358 here here RB 359 363 that that IN 364 369 TRAIL TRAIL NNP 370 371 ( ( ( 371 382 TNF-related tnf-related JJ 383 401 apoptosis-inducing apoptosis-inducing JJ 402 408 ligand ligand NN 408 409 ) ) ) 409 410 , , , 411 412 a a DT 413 421 recently recently RB 422 432 identified identify VBN 433 436 DIL DIL NNP 436 437 , , , 438 442 also also RB 443 452 activates activate VBZ 453 461 NFkappaB nfkappab NN 462 464 in in IN 465 473 lymphoid lymphoid JJ 474 478 cell cell NN 479 484 lines line NNS 485 487 in in IN 488 489 a a DT 490 497 kinetic kinetic JJ 498 505 similar similar JJ 506 508 to to TO 509 517 TNFalpha TNFalpha NNP 517 518 . . . 519 527 NFkappaB NFkappaB NNP 528 536 activity activity NN 537 539 is be VBZ 540 551 independent independent JJ 552 556 from from IN 557 561 FADD FADD NNP 561 562 , , , 563 571 caspases caspas NNS 571 572 , , , 573 576 and and CC 577 586 apoptosis apoptosis NN 587 596 induction induction NN 596 597 . . . 598 600 To to TO 601 606 study study VB 607 610 the the DT 611 620 influence influence NN 621 623 of of IN 624 632 NFkappaB NFkappaB NNP 633 641 activity activity NN 642 644 on on IN 645 654 apoptosis apoptosis NN 655 663 mediated mediate VBN 664 666 by by IN 667 672 TRAIL TRAIL NNP 672 673 , , , 674 678 CD95 CD95 NNP 678 679 , , , 680 688 TNFalpha TNFalpha NNP 688 689 , , , 690 692 or or CC 693 704 doxorubicin doxorubicin NN 704 705 , , , 706 714 NFkappaB NFkappaB NNP 715 725 activation activation NN 726 729 was be VBD 730 739 inhibited inhibit VBN 740 745 using use VBG 746 749 the the DT 750 760 proteasome proteasome NN 761 770 inhibitor inhibitor NN 771 815 N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal n-acetyl-l-leucinyl-l-leucinyl-l-norleucinal JJ 816 818 or or CC 819 828 transient transient JJ 829 843 overexpression overexpression NN 844 846 of of IN 847 853 mutant mutant JJ 854 866 IkappaBalpha IkappaBalpha NNP 866 867 . . . 868 879 Sensitivity sensitivity NN 880 883 for for IN 884 893 induction induction NN 894 896 of of IN 897 906 apoptosis apoptosis NN 907 910 was be VBD 911 919 markedly markedly RB 920 929 increased increase VBN 930 932 by by IN 933 938 these these DT 939 949 treatments treatment NNS 950 952 in in IN 953 962 apoptosis apoptosis NN 963 972 sensitive sensitive JJ 973 977 cell cell NN 978 983 lines line NNS 983 984 . . . 985 993 Moreover moreover RB 993 994 , , , 995 999 both both CC 1000 1002 in in IN 1003 1007 cell cell NN 1008 1013 lines line NNS 1014 1017 and and CC 1018 1020 in in IN 1021 1028 primary primary JJ 1029 1037 leukemia leukemia NN 1038 1043 cells cell NNS 1044 1048 that that WDT 1049 1052 are be VBP 1053 1062 resistant resistant JJ 1063 1070 towards towards IN 1071 1080 induction induction NN 1081 1083 of of IN 1084 1093 apoptosis apoptosis NN 1094 1096 by by IN 1097 1101 DILs dil NNS 1102 1105 and and CC 1106 1117 doxorubicin doxorubicin NN 1117 1118 , , , 1119 1133 antagonization antagonization NN 1134 1136 of of IN 1137 1145 NFkappaB NFkappaB NNP 1146 1154 activity activity NN 1155 1164 partially partially RB 1165 1173 restored restore VBD 1174 1183 apoptosis apoptosis NN 1184 1195 sensitivity sensitivity NN 1195 1196 . . . 1197 1202 These these DT 1203 1207 data datum NNS 1208 1215 suggest suggest VBP 1216 1220 that that IN 1221 1231 inhibition inhibition NN 1232 1234 of of IN 1235 1243 NFkappaB NFkappaB NNP 1244 1254 activation activation NN 1255 1258 may may MD 1259 1266 provide provide VB 1267 1268 a a DT 1269 1278 molecular molecular JJ 1279 1287 approach approach NN 1288 1290 to to TO 1291 1299 increase increase VB 1300 1309 apoptosis apoptosis NN 1310 1321 sensitivity sensitivity NN 1322 1324 in in IN 1325 1335 anticancer anticancer JJ 1336 1345 treatment treatment NN 1345 1346 . . .